Bio-Techne Files Drug Master File With FDA For ExCellerate GMP IPSC Expansion Medium
(RTTNews) - Bio-Techne Corp. (TECH) announced Wednesday that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP), supporting the development and manufacture of regenerative medicine and stem cell therapies.
ExCellerate GMP iPSC Expansion Medium is optimized to support robust expansion and maintenance of stem cell culture for enhanced consistency and reproducibility throughout the stem cell manufacturing process.
The GMP medium complements Bio-Techne's industry leading regenerative medicine therapy workflow solutions, which includes the widest range of GMP cytokines and growth factors available on the market.
The ready-to-use media is manufactured without the use of animal components and is available in preclinical and GMP grades to simplify transition from research to clinic.
The DMF submission provides the FDA with detailed information about the facilities and processes used in the manufacturing, processing, packaging, and storing of ExCellerate GMP iPSC Expansion Medium.
Regenerative medicine and stem cell therapy developers who integrate the medium into their GMP cell manufacturing workflows can easily reference these important details when filing Investigational New Drug (IND) applications with the FDA.
Bio-Techne Q2 Results Miss Estimates; Declares Dividend
Bio-Techne Promotes Kim Kelderman To Succeed Chuck Kummeth As President And CEO
Bio-Techne, Akoya To End Co-development Of RNAscope For Use With PhenoCycler-Fusion System
Bio-Techne To Acquire Namocell For Undisclosed Terms
Australian Market Maintains Early Gains In Mid-market
Asian Markets Trade Mostly Higher
Sensex, Nifty Set To Follow Asian Peers Higher
